<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Medical Journal of the Islamic Republic Of Iran</title>
<title_fa>مجله پزشکی جمهوری اسلامی ایران</title_fa>
<short_title>Med J Islam Repub Iran</short_title>
<subject>Medical Sciences</subject>
<web_url>http://mjiri.iums.ac.ir</web_url>
<journal_hbi_system_id>2</journal_hbi_system_id>
<journal_hbi_system_user>journal2</journal_hbi_system_user>
<journal_id_issn>1016-1430</journal_id_issn>
<journal_id_issn_online>2251-6840</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.18869/mjiri</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1383</year>
	<month>8</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2004</year>
	<month>11</month>
	<day>1</day>
</pubdate>
<volume>18</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>IMMUNOGENICITY OF HEPATITIS B VACCINE IN MULTI - TRANSFUSED THALASSEMIC PATIENTS WITH AND WITHOUT HEPATITIS C INFECTION: A COMP ARA TIVE STUDY WITH HEAL THY CONTROLS</title>
	<subject_fa>Internal Medicine</subject_fa>
	<subject>Internal Medicine</subject>
	<content_type_fa>Original Research: Clinical Science</content_type_fa>
	<content_type>Original Research: Clinical Science</content_type>
	<abstract_fa></abstract_fa>
	<abstract>Hepatitis C virus (HCV) infection is highly prevalent in thalassemic patients,
and this may decrease the serum antibody response to hepatitis B virus (HBV)
vaccine. There is also some alteration of the immune system in multi-transfused
thalassemic patients, as a consequence of iron overload. We investigated whether
HCY infection may reduce the effectiveness of HBY vaccine in multi -
transfused thalassemic patients. Subjects were cited and studied prospectively in
three groups: group I: 125 multi-transfused thalassemic patients with negative
serum HCY antibody group 2: 96 multi-transfused thalassemic patients with
positive serum HCV antibody (ELISA II), in at least 2 different occasions group
3: 100 healthy subjects. Matching was performed between three groups in sex,
age and body mass index and subjects in all groups had negative serum HBsAg,
anti-HBc and anti-HBs and received three 20 flgr/dose injections of recombinant
HBV vaccine (Heberbiovac HB) in months 0, 1, 6. Anti-HBs titer was obtained
one month after the last dose of vaccine and it was considered seroprotective if it
was 2: 10 lUlL. Seroprotection rate was 83.2% in group 1 and 80.2% in group 2
(p=0.74) and was 86% in healthy subjects, which didn't significantly differ with
HCV positive and negative thalassemics (p&gt;0.05). Moreover, the mean values of
ALT among the responders and non-responder thalassemic patients were 55.5 ±
4 l .9 and 57.4 ± 48.5 U/L respectively(p=0.802). During vaccination periods,
patients in all 3 groups did not show any significant adverse reactions. Our study
shows that three standard doses of HBV vaccine are immunogenic and safe in
multi-transfused thalassemic patients with or without HCV infection.
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Hepatitis B, Hepatitis C, Thalassemia, Hepatitis B vaccine. anti-HBs, seroprotection</keyword>
	<start_page>211</start_page>
	<end_page>217</end_page>
	<web_url>http://mjiri.iums.ac.ir/browse.php?a_code=A-10-298-49&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>H</first_name>
	<middle_name></middle_name>
	<last_name>FOROUTAN</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846003397</code>
	<orcid>20031947532846003397</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>From the Department of1nternal Medicine.Imom Hospital. Tehran University of Medical Sciences,</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>H</first_name>
	<middle_name></middle_name>
	<last_name>GHOFRANI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846003398</code>
	<orcid>20031947532846003398</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>SH</first_name>
	<middle_name></middle_name>
	<last_name>. MIRMOMEN</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846003399</code>
	<orcid>20031947532846003399</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>S</first_name>
	<middle_name></middle_name>
	<last_name>KAZEMI ASL</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846003400</code>
	<orcid>20031947532846003400</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>MJ</first_name>
	<middle_name></middle_name>
	<last_name>FARAHVASH</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846003401</code>
	<orcid>20031947532846003401</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>M</first_name>
	<middle_name></middle_name>
	<last_name>NASIRI TOUSI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846003402</code>
	<orcid>20031947532846003402</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
